Plasmacytoid Dendritic Cell – Function & Importance

What are plasmacytoid dendritic cells?

Plasmacytoid dendritic cells (pDCs) are a specialized subset of dendritic cells – a group of immune cells belonging to the innate immune system. They were named “plasmacytoid” due to their morphological resemblance to plasma cells (antibody-producing B cells). In the blood, they account for only about 0.1–0.5% of all mononuclear cells, making them one of the rarest immune cell types in the human body.

Despite their low numbers, pDCs are functionally extraordinary: they are the primary producers of type I interferons (particularly interferon-alpha and interferon-beta) in the entire immune system. These signaling molecules are essential for the early antiviral defense of the body.

Development and distribution

Like all blood cells, plasmacytoid dendritic cells originate in the bone marrow from pluripotent hematopoietic stem cells. Compared to other dendritic cells, they undergo a unique differentiation process in which both myeloid and lymphoid progenitor cells may be involved – their exact lineage is subject to ongoing research.

In their resting state, pDCs mainly circulate in the blood and lymphoid organs (spleen, lymph nodes, thymus). During infection or inflammatory reactions, they migrate into the affected tissue, where they exert their immunostimulatory functions.

Function and mechanism of action

Recognition of pathogens

Plasmacytoid dendritic cells recognize pathogenic structures through pattern recognition receptors (PRRs). Particularly important are Toll-like receptors TLR7 and TLR9, located in intracellular compartments (endosomes), which recognize single-stranded RNA (ssRNA) and unmethylated CpG-DNA, respectively – molecular patterns typical of viruses and bacteria.

Production of type I interferons

Following activation by a pathogen, pDCs rapidly produce enormous quantities of interferon-alpha (IFN-α) and interferon-beta (IFN-β). These cytokines act on neighboring cells, inducing an antiviral state, inhibiting viral replication, and activating natural killer (NK) cells as well as cytotoxic T lymphocytes. This process is critical for the early containment of viral infections.

Bridging innate and adaptive immunity

Beyond their role as interferon producers, pDCs can also function as antigen-presenting cells. They take up antigens, process them, and present them on MHC class I and MHC class II molecules, thereby activating T lymphocytes and initiating the adaptive immune response. This makes pDCs an important bridge between rapid innate immunity and the more specific adaptive immune defense.

Clinical significance

Viral infectious diseases

In infections caused by viruses such as influenza, HIV, SARS-CoV-2, or hepatitis C, pDCs play a crucial role. They are often among the first immune cell populations to respond to a viral infection and contribute substantially to controlling early viral spread.

Autoimmune diseases

Excessive or misdirected activation of pDCs can contribute to the development of autoimmune diseases. In systemic lupus erythematosus (SLE) in particular, pDCs continuously produce large amounts of IFN-α, triggered by self-derived nucleic acids. This chronic interferon production is considered a central driver of lupus pathogenesis.

Allergies and immune tolerance

Plasmacytoid dendritic cells are also involved in the regulation of immunological tolerance. Under certain conditions, they can induce regulatory T cells (Tregs), thereby dampening excessive immune responses. Dysfunctional pDCs have been linked to the development of allergic diseases and asthma.

Cancer immunology

In tumors, pDCs infiltrate the tumor microenvironment but are frequently driven into a tolerogenic (immunosuppressive) state. This can weaken the anti-tumor immune response. At the same time, pDCs are being investigated as potential targets for cancer vaccines and immunotherapies.

Neoplasms

In rare cases, pDCs themselves can undergo malignant transformation, giving rise to blastic plasmacytoid dendritic cell neoplasm (BPDCN), a rare and aggressive hematological malignancy that preferentially affects older men and can involve the skin, bone marrow, and blood.

Diagnostics

Plasmacytoid dendritic cells are typically identified and characterized by flow cytometry. Typical surface markers in humans include:

• CD123 (IL-3 receptor, highly expressed)
• BDCA-2 (CD303) and BDCA-4 (CD304) – pDC-specific markers
• CD4 (low expression)
• Absence of myeloid markers (CD11c, CD14) and lymphoid markers (CD3, CD19, CD56)

Measurement of IFN-α levels in the blood can indirectly indicate pDC activation and is used in the diagnostics of SLE and related conditions.

Therapeutic relevance and outlook

Due to their central immunological importance, pDCs are an active area of research. Therapeutic approaches include:

• Blocking TLR7/TLR9 to reduce IFN-α production in autoimmune diseases
• Activating pDCs to enhance antiviral or antitumoral immune responses
• pDC-based vaccines in cancer immunotherapy
• Anifrolumab (an IFN receptor blocker approved for SLE) as an indirect approach to inhibit pDC-mediated IFN signaling

References

1. Colonna M, Trinchieri G, Liu YJ. Plasmacytoid dendritic cells in immunity. Nature Immunology. 2004;5(12):1219-1226.
2. Reizis B. Plasmacytoid Dendritic Cells: Development, Regulation, and Function. Immunity. 2019;50(1):37-50.
3. World Health Organization (WHO). Innate Immunity and Antiviral Defense Mechanisms. WHO Technical Report Series, 2021.